Clinical Trial Update: TAF Switch in F3/4 CHB pt With Partial Response to NUC (ESTAB-AFPVR) [Phase 4]

View source ↗

Summary

Phase 4 clinical trial update on TAF switch in hepatitis B patients with partial response to nucleos(t)ide therapy (ESTAB-AFPVR).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fibrosis and Cirrhosis of the Liver
• Hepatitis B

Drugs mentioned

• TAF (tenofovir alafenamide)

Snippet

Sponsor: Kaohsiung Medical University Chung-Ho Memorial Hospital | Conditions: Hepatitis B, Fibrosis and Cirrhosis of Liver | Phase 4 | Status: UNKNOWN